• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

浆细胞样树突状细胞浸润卵巢癌与预后不良相关。

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis.

机构信息

Université de Lyon; Lyon, France ; Université Lyon 1; ISPB; Lyon, France ; INSERM; U1052; Centre de Recherche en Cancérologie de Lyon; Lyon, France ; Cnrs; UMR5286; Centre de Recherche en Cancérologie de Lyon; Lyon, France ; LabEx DEVweCAN; Lyon, France ; Department of Medical Oncology; Centre Léon Bérard; Lyon, France.

出版信息

Oncoimmunology. 2012 May 1;1(3):380-382. doi: 10.4161/onci.18801.

DOI:10.4161/onci.18801
PMID:22737622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3382863/
Abstract

Using two different and complementary approaches (flow cytometry and immunohistochemistry) on two independent cohorts of ovarian cancer patients, we found that accumulation of plasmacytoid dendritic cells (pDC) in tumors is associated with early relapse. This deleterious effect of tumor-associated pDC was evident when they are present in cancer epithelium but not in lymphoid aggregates.

摘要

通过对两批独立的卵巢癌患者使用两种不同且互补的方法（流式细胞术和免疫组织化学），我们发现肿瘤中浆细胞样树突状细胞（pDC）的积累与早期复发相关。当肿瘤相关的 pDC 存在于癌上皮中而不存在于淋巴聚集物中时，这种有害作用是明显的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc48/3382863/29b804cc3d8d/onci-1-380-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc48/3382863/29b804cc3d8d/onci-1-380-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc48/3382863/29b804cc3d8d/onci-1-380-g1.jpg

相似文献

1
Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis.浆细胞样树突状细胞浸润卵巢癌与预后不良相关。
Oncoimmunology. 2012 May 1;1(3):380-382. doi: 10.4161/onci.18801.
2
Increased tumor-infiltrating plasmacytoid dendritic cells predicts poor prognosis in oral squamous cell carcinoma.肿瘤浸润性浆细胞样树突状细胞增多预示着口腔鳞状细胞癌预后不良。
Arch Oral Biol. 2017 Jun;78:129-134. doi: 10.1016/j.archoralbio.2017.02.012. Epub 2017 Feb 10.
3
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.浆细胞样树突状细胞的数量和功能改变有助于卵巢癌的免疫耐受。
Cancer Res. 2011 Aug 15;71(16):5423-34. doi: 10.1158/0008-5472.CAN-11-0367. Epub 2011 Jun 22.
4
Increased tumor-infiltrating plasmacytoid dendritic cells promote cancer cell proliferation and invasion via TNF-α/NF-κB/CXCR-4 pathway in oral squamous cell carcinoma.肿瘤浸润浆细胞样树突状细胞增多通过TNF-α/NF-κB/CXCR-4途径促进口腔鳞状细胞癌的癌细胞增殖和侵袭。
J Cancer. 2021 Mar 19;12(10):3045-3056. doi: 10.7150/jca.55580. eCollection 2021.
5
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.浆细胞样树突状细胞 IFN-α 产生受损有利于调节性 T 细胞的扩增，这可能有助于乳腺癌的进展。
Cancer Res. 2012 Oct 15;72(20):5188-97. doi: 10.1158/0008-5472.CAN-11-3468. Epub 2012 Jul 25.
6
[Anti-lung cancer effect of myeloid and plasmacytoid dendritic cell combined vaccines loaded with tumor cell lysates in vitro].[负载肿瘤细胞裂解物的髓样和浆细胞样树突状细胞联合疫苗体外抗肺癌作用]
Zhonghua Zhong Liu Za Zhi. 2019 Jul 23;41(7):501-507. doi: 10.3760/cma.j.issn.0253-3766.2019.07.004.
7
The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse Models.肿瘤微环境在人源化小鼠模型中促进功能性人肿瘤驻留浆细胞样树突状细胞的生成。
Front Immunol. 2020 Sep 8;11:2082. doi: 10.3389/fimmu.2020.02082. eCollection 2020.
8
Enumeration of bone marrow plasmacytoid dendritic cells by multiparameter flow cytometry as a prognostic marker following allogeneic hematopoietic stem cell transplantation.通过多参数流式细胞术对骨髓浆细胞样树突状细胞进行计数，作为异基因造血干细胞移植后的一种预后标志物。
Blood Cells Mol Dis. 2018 Mar;69:107-112. doi: 10.1016/j.bcmd.2017.10.004. Epub 2017 Oct 31.
9
Plasmacytoid dendritic cells in pulmonary lymphoid follicles of patients with COPD.COPD 患者肺部淋巴滤泡中的浆细胞样树突状细胞。
Eur Respir J. 2010 Oct;36(4):781-91. doi: 10.1183/09031936.00140409. Epub 2010 Mar 29.
10
Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation.流式细胞术鉴定具有浆细胞样树突状细胞分化的髓系肿瘤的成熟谱。
Cytometry B Clin Cytom. 2020 Jan;98(1):43-51. doi: 10.1002/cyto.b.21761. Epub 2019 Jan 5.

引用本文的文献

1
Dermatopathological Challenges in Objectively Characterizing Immunotherapy Response in Mycosis Fungoides.蕈样肉芽肿免疫治疗反应客观特征化中的皮肤病理学挑战
Dermatopathology (Basel). 2025 Jul 29;12(3):22. doi: 10.3390/dermatopathology12030022.
2
Multi-omics and functional characterization of the tumor-killing capacity of Imiquimod-activated plasmacytoid dendritic cells.咪喹莫特激活的浆细胞样树突状细胞杀瘤能力的多组学及功能表征
iScience. 2025 May 14;28(6):112670. doi: 10.1016/j.isci.2025.112670. eCollection 2025 Jun 20.
3
Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements.

本文引用的文献

1
Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.肿瘤内中性粒细胞和浆细胞样树突状细胞预示着不良预后，并与 AJCC Ⅰ/Ⅱ期黑色素瘤中 pSTAT3 的表达相关。
Cancer. 2012 May 1;118(9):2476-85. doi: 10.1002/cncr.26511. Epub 2011 Sep 22.
2
Plasmacytoid dendritic cells and cancer.浆细胞样树突状细胞与癌症。
J Leukoc Biol. 2011 Oct;90(4):681-90. doi: 10.1189/jlb.0411190. Epub 2011 Jul 5.
3
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.
肿瘤微环境在卵巢癌转移及临床进展中的作用
J Transl Med. 2025 May 14;23(1):539. doi: 10.1186/s12967-025-06508-0.
4
The complement system and kidney cancer: pathogenesis to clinical applications.补体系统与肾癌：从发病机制到临床应用
J Clin Invest. 2025 May 1;135(9). doi: 10.1172/JCI188351.
5
Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.肿瘤浸润性髓样细胞；机制、功能意义及在癌症治疗中的靶向作用
Cell Oncol (Dordr). 2025 Feb 25. doi: 10.1007/s13402-025-01051-y.
6
Tumor-Infiltrating Immune Cells in Colorectal Cancer.结直肠癌中的肿瘤浸润免疫细胞
Neoplasia. 2025 Jan;59:101091. doi: 10.1016/j.neo.2024.101091. Epub 2024 Dec 5.
7
Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy.工程树突状细胞仿生膜作为肿瘤靶向治疗的递送系统。
J Nanobiotechnology. 2024 Oct 27;22(1):663. doi: 10.1186/s12951-024-02913-7.
8
Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling.浆细胞样树突状细胞在抗肿瘤免疫的最前沿：重塑肿瘤微环境的重布线策略。
J Exp Clin Cancer Res. 2024 Jul 17;43(1):196. doi: 10.1186/s13046-024-03121-9.
9
Inhibitory receptors of plasmacytoid dendritic cells as possible targets for checkpoint blockade in cancer.浆细胞样树突状细胞的抑制性受体作为癌症检查点阻断治疗的潜在靶点。
Front Immunol. 2024 Mar 5;15:1360291. doi: 10.3389/fimmu.2024.1360291. eCollection 2024.
10
Macrophage barrier in the tumor microenvironment and potential clinical applications.肿瘤微环境中的巨噬细胞屏障及其潜在临床应用
Cell Commun Signal. 2024 Jan 26;22(1):74. doi: 10.1186/s12964-023-01424-6.
浆细胞样树突状细胞的数量和功能改变有助于卵巢癌的免疫耐受。
Cancer Res. 2011 Aug 15;71(16):5423-34. doi: 10.1158/0008-5472.CAN-11-0367. Epub 2011 Jun 22.
4
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.伊马替尼联合聚乙二醇干扰素 α-2a 治疗慢性髓性白血病。
N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.
5
Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer.Toll 样受体 7 和 9 信号转导受损：从慢性病毒感染到癌症。
Trends Immunol. 2010 Oct;31(10):391-7. doi: 10.1016/j.it.2010.07.004. Epub 2010 Sep 9.
6
Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses.干扰素-α调节人激活的调节性和效应性 T 细胞之间的动态平衡：对抗病毒和自身免疫反应的影响。
Immunology. 2010 Sep;131(1):107-17. doi: 10.1111/j.1365-2567.2010.03280.x. Epub 2010 May 6.
7
Interferons, immunity and cancer immunoediting.干扰素、免疫与癌症免疫编辑
Nat Rev Immunol. 2006 Nov;6(11):836-48. doi: 10.1038/nri1961.
8
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia.伊马替尼与慢性髓性白血病患者浆细胞样树突状细胞功能
Blood. 2004 Jun 15;103(12):4666-8. doi: 10.1182/blood-2003-09-3220. Epub 2004 Jan 8.
9
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
Gynecol Oncol. 1999 Jul;74(1):48-52. doi: 10.1006/gyno.1999.5455.